In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...
University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.